Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis

Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic therapy 2019-01, Vol.32 (1), p.e12758-n/a
Hauptverfasser: Gilbert, Morgan, Scherrer, Leigh Ann
Format: Artikel
Sprache:eng
Schlagworte:
Cyclosporine
Stevens‐Johnson syndrome
Toxic Epidermal Necrosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 1
container_start_page e12758
container_title Dermatologic therapy
container_volume 32
creator Gilbert, Morgan
Scherrer, Leigh Ann
description Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. Five case series and one meta‐analysis were analyzed. From review of the existing literature, cyclosporine appears to not only have a mortality benefit in the treatment of SJS/TEN, but also a relatively safe side effect profile.
doi_str_mv 10.1111/dth.12758
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_dth_12758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DTH12758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3608-b5dc9eca2b1af896af58bff65ea008de7cfb32dfc7f96c50da461c2e32e8390f3</originalsourceid><addsrcrecordid>eNp1kLtOwzAUhi0EolAYeAHklSGtLyS1R1QKBVVioMzBsY9Vo8SO4nDJxjvwhjwJoQE2znLO8P3_kT6ETiiZ0H6mpt1MKJulYgcd0JTJRBAqd_ubyywhTGYjdBjjEyGUSU730YgTJlJOxAF6XFjrtNIdVt7gqCy0HQ4W606XIdahcR6w8_i-hRfw8fP94zZsfAwex86bJlSwDbbhzWkMtTPQVKrEHnQTyi66eIT2rCojHP_sMXq4Wqzny2R1d30zv1glmmdEJEVqtAStWEGVFTJTNhWFtVkKihBhYKZtwZmxemZlplNi1HlGNQPOQHBJLB-js6G3fxxjAzavG1eppsspyb8t5b2lfGupZ08Htn4uKjB_5K-WHpgOwKsrofu_Kb9cL4fKL555dVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Gilbert, Morgan ; Scherrer, Leigh Ann</creator><creatorcontrib>Gilbert, Morgan ; Scherrer, Leigh Ann</creatorcontrib><description>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. Five case series and one meta‐analysis were analyzed. From review of the existing literature, cyclosporine appears to not only have a mortality benefit in the treatment of SJS/TEN, but also a relatively safe side effect profile.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/dth.12758</identifier><identifier>PMID: 30285308</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Cyclosporine ; Stevens‐Johnson syndrome ; Toxic Epidermal Necrosis</subject><ispartof>Dermatologic therapy, 2019-01, Vol.32 (1), p.e12758-n/a</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3608-b5dc9eca2b1af896af58bff65ea008de7cfb32dfc7f96c50da461c2e32e8390f3</citedby><cites>FETCH-LOGICAL-c3608-b5dc9eca2b1af896af58bff65ea008de7cfb32dfc7f96c50da461c2e32e8390f3</cites><orcidid>0000-0001-5982-1629 ; 0000-0002-9678-4270</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdth.12758$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdth.12758$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30285308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gilbert, Morgan</creatorcontrib><creatorcontrib>Scherrer, Leigh Ann</creatorcontrib><title>Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. Five case series and one meta‐analysis were analyzed. From review of the existing literature, cyclosporine appears to not only have a mortality benefit in the treatment of SJS/TEN, but also a relatively safe side effect profile.</description><subject>Cyclosporine</subject><subject>Stevens‐Johnson syndrome</subject><subject>Toxic Epidermal Necrosis</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUhi0EolAYeAHklSGtLyS1R1QKBVVioMzBsY9Vo8SO4nDJxjvwhjwJoQE2znLO8P3_kT6ETiiZ0H6mpt1MKJulYgcd0JTJRBAqd_ubyywhTGYjdBjjEyGUSU730YgTJlJOxAF6XFjrtNIdVt7gqCy0HQ4W606XIdahcR6w8_i-hRfw8fP94zZsfAwex86bJlSwDbbhzWkMtTPQVKrEHnQTyi66eIT2rCojHP_sMXq4Wqzny2R1d30zv1glmmdEJEVqtAStWEGVFTJTNhWFtVkKihBhYKZtwZmxemZlplNi1HlGNQPOQHBJLB-js6G3fxxjAzavG1eppsspyb8t5b2lfGupZ08Htn4uKjB_5K-WHpgOwKsrofu_Kb9cL4fKL555dVQ</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Gilbert, Morgan</creator><creator>Scherrer, Leigh Ann</creator><general>John Wiley &amp; Sons, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5982-1629</orcidid><orcidid>https://orcid.org/0000-0002-9678-4270</orcidid></search><sort><creationdate>201901</creationdate><title>Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis</title><author>Gilbert, Morgan ; Scherrer, Leigh Ann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3608-b5dc9eca2b1af896af58bff65ea008de7cfb32dfc7f96c50da461c2e32e8390f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cyclosporine</topic><topic>Stevens‐Johnson syndrome</topic><topic>Toxic Epidermal Necrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gilbert, Morgan</creatorcontrib><creatorcontrib>Scherrer, Leigh Ann</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gilbert, Morgan</au><au>Scherrer, Leigh Ann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2019-01</date><risdate>2019</risdate><volume>32</volume><issue>1</issue><spage>e12758</spage><epage>n/a</epage><pages>e12758-n/a</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. Five case series and one meta‐analysis were analyzed. From review of the existing literature, cyclosporine appears to not only have a mortality benefit in the treatment of SJS/TEN, but also a relatively safe side effect profile.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>30285308</pmid><doi>10.1111/dth.12758</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-5982-1629</orcidid><orcidid>https://orcid.org/0000-0002-9678-4270</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1396-0296
ispartof Dermatologic therapy, 2019-01, Vol.32 (1), p.e12758-n/a
issn 1396-0296
1529-8019
language eng
recordid cdi_crossref_primary_10_1111_dth_12758
source Wiley Online Library - AutoHoldings Journals
subjects Cyclosporine
Stevens‐Johnson syndrome
Toxic Epidermal Necrosis
title Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T20%3A35%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20cyclosporine%20in%20Stevens%E2%80%93Johnson%20syndrome%20and%20toxic%20epidermal%20necrolysis&rft.jtitle=Dermatologic%20therapy&rft.au=Gilbert,%20Morgan&rft.date=2019-01&rft.volume=32&rft.issue=1&rft.spage=e12758&rft.epage=n/a&rft.pages=e12758-n/a&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/dth.12758&rft_dat=%3Cwiley_cross%3EDTH12758%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30285308&rfr_iscdi=true